Cambridge biotech STORM Therapeutics raises $56M
STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by existing investors including Pfizer Ventures and M Ventures. STORM Therapeutics, a Cambridge-based clinical-stage biotech targeting RNA modifications to treat cancer, has raised $56 million in […]<br /> This story continues at The Next Web [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
Cambridge Audio unveils three wireless bookshelf speakers at CES
Cambridge Audio has three new active speakers at CES 2026. The L/R Series is a trio of active bookshelf-style speakers, each with wired and wireless modes.The flagship L/R X is an 800W model (400W per [...]
The new Storm Radar app is a treasure trove of data for weather nerds
The horrible winter of 2026 is behind us in New England; now we’ve moved on to the season where there’s a threat of rain basically every day. Given that, the updated Storm Radar app from The Weath [...]
Stanford is running 37,000 AI agents as a virtual biotech — and one of its drug designs got independently confirmed by Merck
For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate professor of biomedical data science a [...]
UCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune disease
The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseas [...]
Cambridge Aerospace is in talks to raise $300M at a $3.5bn valuation, almost nine times its worth a year ago
Cambridge Aerospace, a British defence-technology startup building systems to shoot down drones and cruise missiles, is in talks to raise around $300M at a valuation of about $3.5bn, according to a Bl [...]
The Last of Us season two 'The Path' recap: The calm after the storm before the storm
There’s an understandable and undeniable pall hanging over The Last of Us after last week’s shocker. And it’s the calm before the storm that’ll make up the rest of the season: Ellie and Dina†[...]
Viking Therapeutics closer to bringing its Ozempic competitor to market
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year partnership with CordenPharma, a leading contract manufacturing firm.Read more... [...]